STAT3 and cancer: While decoy oligonucleotides have successfully decreased the STAT3-induced transcriptional gene expression in a variety of cancers including head and neck [188], ovarian [189], prostate [190], and hepatocellular carcinoma [191], in vivo application has been limited by plasma instability [192].